Status:
COMPLETED
Second Line Breast Cancer Trial
Lead Sponsor:
AstraZeneca
Conditions:
Advanced Breast Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE3
Brief Summary
The main purpose of this study is to compare the effect of 2 doses of FASLODEX with 1 dose of ARIMIDEX in terms of time to tumor progression in postmenopausal women with advanced breast cancer.
Eligibility Criteria
Inclusion
- postmenopausal women with confirmation of breast cancer
- objective evidence of recurrence or progression of breast cancer no more than 1 prior hormonal therapy for breast cancer
Exclusion
- presence of life-threatening metastatic visceral disease
- previous treatment with FASLODEX, ARIMIDEX or any aromatase inhibitor for breast cancer
- more than 1 prior endocrine medical treatment for advanced breast cancer .
Key Trial Info
Start Date :
May 1 1997
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2004
Estimated Enrollment :
588 Patients enrolled
Trial Details
Trial ID
NCT00635713
Start Date
May 1 1997
End Date
September 1 2004
Last Update
April 10 2009
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.